Extended Data Fig. 3: Clinical results across sex, etiologic disease subgroups, and TKI treatment. | Nature Medicine

Extended Data Fig. 3: Clinical results across sex, etiologic disease subgroups, and TKI treatment.

From: Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

Extended Data Fig. 3

No apparent correlation of etiology (a-c), gender (male, n = 24; female, n = 10) (d), and time on TKI at baseline (PD, n = 14; SD, n = 9; PR/CR, n = 11) (e) with BOR. Note: 1 CR patient had a previous history of both HCV and HBV infection and is shown marked with an (*) in both (b) and (c). d, e, Data are presented as mean ± SEM. Significance was tested by a two-tailed, Mann-Whitney statistical analysis.

Back to article page